Crinetics Announces FDA Approval of PALSONIFY™ (Paltusotine) for the Treatment of Adults with ...

With FDA Nod in Rare Hormone Disease, Crinetics Can Challenge Blockbuster Meds From Novartis, Ipsen

FDA approval of Crinetics Pharmaceuticals’ Palsonify makes it the first oral first-line therapy for acromegaly, a rare endocrine disorder. The once-daily pill will compete with blockbuster acromegaly drugs from Novartis and Ipsen that are administered as injections. The post With FDA Nod in Rare Hormone Disease, Crinetics Can Challenge Blockbuster Meds From Novartis, Ipsen appeared first on MedCity News.

Orsini Selected as Specialty Pharmacy Partner for Crinetics' PALSONIFY™ (paltusotine)

PALSONIFY is an FDA-approved once-daily, oral therapy for the treatment of acromegaly

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with ...

Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly

Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly

Paltusotine Receives FDA Approval to Treat Acromegaly in Adults | Pharmacy Times - Pharmacy Practice News and Expert Insights

Paltusotine, the first oral treatment for acromegaly, offers hope for improved patient care and management.

Paltusotine FDA Approved for Acromegaly in Adults

The approval of paltusotine (Palsonify; Crinetics) marks the first for a once-daily, oral therapy to treat acromegaly.